Here is the prepub not fully peer reviewed Pfizer Phase 3 ( mostly ) 6 month study update (seems mostly pre delta data when South African variant was of concern). The study result show a drop in efficacy over time with 4 months since vaccinated until data cutoff the efficacy is 83.7%.(Pre delta data)
Background BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine encoding a prefusion-stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. BNT162b2 is highly efficacious against COVID-19 and is currently authorized for emergency use or conditional approval...
www.medrxiv.org
Over 42000 participants worldwide, with about 12,000 ( not 15000) vaccinated through Oct 2020 worldwide.
My bout with covid in June as part of the study is likely not reflected because it is likely after data cutoff, as is any other subject events post data cutoff.